Jeffrey Tosoian, MD, MPH
Medical School: Johns Hopkins University School of Medicine
Residency: Johns Hopkins Medical Institutions
Fellowship: University of Michigan, Urologic Oncology and Translational Cancer Research
Clinical Interests: Elevated PSA, Prostate Cancer, Kidney Cancer, Bladder Cancer, Testis Cancer
Jeffrey Tosoian, MD, MPH is an Associate Professor and the Director of Translational Cancer Research in the Department of Urology at Vanderbilt University Medical Center (VUMC). He completed medical school and urology residency at Johns Hopkins, where he obtained an MPH in epidemiological and biostatistical methods for clinical research. He then completed a translational research and clinical fellowship in urologic oncology at the University of Michigan. Dr. Tosoian is the Chair of the National Cancer Institute’s Early Detection Research Network Genitourinary Cancer Collaborative and the American Cancer Society’s National Prostate Cancer Roundtable for localized prostate cancer. His research is focused on the development and clinical application of non-invasive tools for early detection and management of prostate cancer and has been supported by the National Cancer Institute SPORE Career Enhancement Program, the Prostate Cancer Foundation, and the NIH/NCI Early Detection Research Network. Dr. Tosoian leads the Prostate Cancer Risk Clinic, a clinical program for early screening in patients at increased genetic risk of prostate cancer. His clinical practice is primarily at the Nashville VA Medical Center, where he treats patients with urologic cancers.
Highlighted Publications
Tosoian JJ, Penson DF, Chinnaiyan AM. A Pragmatic Approach to Prostate Cancer Screening. JAMA. 2024 May;331(17):1448-1450. doi: 10.1001/jama.2024.4089. PMID: 38581253.
Tosoian JJ, Zhang Y, Xiao L, Xie C, Samora NL, Niknafs YS, Chopra Z, Siddiqui J, Zheng H, Herron G, Vaishampayan N, Robinson HS, Arivoli K, Trock BJ, Ross AE, Morgan TM, Palapattu GS, Salami SS, Kunju LP, Tomlins SA, Sokoll LJ, Chan DW, Srivastava S, Feng Z, Sanda MG, Zheng Y, Wei JT, Chinnaiyan AM; EDRN-PCA3 Study Group. Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer. JAMA Oncol. 2024 Jun;10(6):726-736. doi: 10.1001/jamaoncol.2024.0455. PMID: 38635241.
Robinson HS, Lee SS, Barocas DA, Tosoian JJ. Evaluation of blood and urine based biomarkers for detection of clinically-significant prostate cancer. Prostate Cancer Prostatic Dis. 2024 Jun 10. doi: 10.1038/s41391-024-00840-0. Online ahead of print. PMID: 38858447
Clinical Validation of MyProstateScore 2.0 Testing Using First-Catch, Non-Digital Rectal Examination Urine. Tosoian JJ, Zhang Y, Meyers JI, Heaton S, Siddiqui J, Xiao L, Assani KD, Barocas DA, Ross AE, Chopra Z, Herron GC, Edelson JA, Graham NJ, Singhal U, Salami SS, Morgan TM, Palapattu GS, Wei JT, Chinnaiyan AM.J Urol. 2025 Jan 21:101097JU0000000000004421. doi: 10.1097/JU.0000000000004421. Online ahead of print.PMID: 39836866